Travere Therapeutics, Inc. 2.5% 15-SEP-2025Travere Therapeutics, Inc. 2.5% 15-SEP-2025Travere Therapeutics, Inc. 2.5% 15-SEP-2025

Travere Therapeutics, Inc. 2.5% 15-SEP-2025

No trades
See on Supercharts

Key terms


Outstanding amount
‪68.90 M‬USD
Face value
1,000.00USD
Minimum denomination
1,000.00USD
Coupon
2.50% (Fixed)
Coupon frequency
Semi-annual
Yield to maturity
6.90%
Maturity date
Sep 15, 2025
Term to maturity
11 months

About Travere Therapeutics, Inc. 2.5% 15-SEP-2025


Sector
Health Technology
Home page
Issue date
Sep 10, 2018
FIGI
BBG00LWSMG97
Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.
Advanced bond data for paid plans
Unlock important bond data including coupon rates, redemption details, risk assessments, and much more.